Home/Pipeline/M107

M107

Gastroparesis

Phase 2Active

Key Facts

Indication

Gastroparesis

Phase

Phase 2

Status

Active

Company

Aclipse Therapeutics

About Aclipse Therapeutics

Aclipse Therapeutics is a private, clinical-stage biotech founded in 2018 and headquartered in Durham, North Carolina. The company is transitioning from preclinical to clinical development with two lead small molecule candidates: M107, poised for a Phase 2 trial in gastroparesis, and M102, targeting a Phase 1 trial in ALS. Aclipse's strategy integrates drug development with patient stratification biomarker approaches to improve clinical outcomes, backed by a management team with a strong track record in drug development and business transactions.

View full company profile

Therapeutic Areas

Gastroenterology Neurology Neuromuscular

Other Gastroparesis Drugs

Drug	Company	Phase	Status
TAGSS Pyloroplasty	Endo-TAGSS	Pre-clinical	Active
Naronapride (ATI-7505)	Renexxion	Phase 2b	Active
Real-World Evidence & Post-Market Surveillance	Enterra Medical	Post-Market	Active
Astressin Platform	Sentia Medical Sciences	Pre-clinical	Active
NEREUS™ (tradipitant)	Vanda Pharmaceuticals	Development	Active
ABP-450	AEON Biopharma	Research	Research